Emilio Sulpizio, MD
Hematology & Oncology · Spokane, WANPI 1730543117
Payments from drug & device makers
Across 131 payments — averaging $277.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biontech SE$23K
- Astrazeneca UK Limited$11K
- Novartis$263
- Amgen$259
- Lilly USA, LLC$161
- Incyte Corporation$148
- plus $1K from 33 others
What the payments were for
- Food & beverage$1,98690%
- Education$21010%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biontech SE | 24 | $23,124 |
| Astrazeneca UK Limited | 1 | $11,036 |
| Novartis | 15 | $263 |
| Amgen | 11 | $259 |
| Lilly USA, LLC | 3 | $161 |
| Incyte Corporation | 5 | $148 |
| Merck | 9 | $148 |
| AstraZeneca(2 entities) | 6 | $146 |
| EMD Serono, Inc. | 6 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $79 |
| Karyopharm Therapeutics Inc. | 2 | $64 |
| GSK | 3 | $61 |
| AbbVie | 3 | $53 |
| Foundation Medicine, Inc. | 3 | $49 |
| Seagen Inc. | 3 | $49 |
| Deciphera Pharmaceuticals Inc. | 2 | $45 |
| Sanofi | 2 | $43 |
| Dova Pharmaceuticals | 2 | $40 |
| Bayer | 2 | $39 |
| Astellas Pharma US Inc | 2 | $38 |
| Bristol Myers Squibb | 2 | $37 |
| Rigel Pharmaceuticals, Inc. | 1 | $28 |
| Puma Biotechnology, Inc. | 1 | $28 |
| Ipsen Biopharmaceuticals, Inc | 2 | $26 |
| Johnson & Johnson(2 entities) | 2 | $26 |
| Gilead | 1 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Blueprint Medicines Corporation | 1 | $23 |
| Partner Therapeutics, Inc. | 1 | $22 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $22 |
| AMAG Pharmaceuticals, Inc. | 1 | $21 |
| Acrotech Biopharma Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Beigene USA, Inc. | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
| Aurobindo Pharma USA, Inc. | 1 | $14 |
| Secura Bio, Inc. | 2 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,357 in reported general payments places this provider in the 55th percentile of 349 hematology & oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 47 | $781,703 |
| Lenalidomide | 35 | $437,789 |
| RevlimidLenalidomide | 14 | $227,718 |
| CalquenceAcalabrutinib Maleate | 12 | $205,087 |
| BrukinsaZanubrutinib | 12 | $179,910 |
| Abiraterone Acetate | 23 | $53,903 |
| EliquisApixaban | 68 | $44,116 |
| XareltoRivaroxaban | 21 | $13,533 |
| ValacyclovirValacyclovir Hcl | 20 | $1,413 |
| Anastrozole | 104 | $1,026 |
| Dexamethasone | 55 | $901 |
| Imatinib Mesylate | 11 | $797 |
| Hydroxyurea | 29 | $728 |
| Tamoxifen Citrate | 16 | $573 |
| Acyclovir | 31 | $435 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $22 | $781,70347 claims |
| Bristol Myers SquibbRevlimid | $37 | $227,71814 claims |
| AstraZenecaCalquence | $146 | $205,08712 claims |
| Beigene USA, Inc.Brukinsa | $20 | $179,91012 claims |
| Johnson & JohnsonXarelto | $26 | $13,53321 claims |
| Lilly USA, LLCOlanzapine | $161 | $5911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 349 hematology & oncology providers in Washington.
Other hematology & oncology in Spokane
- Arvind ChaudhrySpokane$11.5M
- Mazyar ShadmanSeattle$36.8M
- Ryan CassadaySeattle$22.7M
- John PesandoSeattle$15.7M
- Andrew CowanSeattle$15M
- Stephen SmithSeattle$12.6M
- Sibel BlauPuyallup$11.9M
- Stephanie LeeSeattle$11.2M
- Sara HurvitzSeattle$10.9M
- Chaitra UjjaniSeattle$10.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.